





This reimbursement guide, for radio frequency ablation, provides coding and payment information for physicians and facilities to receive Medicare reimbursement. The Medicare payment amounts provided are national average payments. Actual reimbursement will vary based on different factors.

Payer policies will vary and should be verified prior to treatment for limitations on diagnosis, coding, or site of service requirements. The coding options listed within this guide are commonly used codes and are not intended to be an all-inclusive list. We recommend consulting your relevant manuals for appropriate coding options.

This guide is intended to fully inform users. Sites of services must be based upon each patient's acuity of care needs. For radio frequency ablation procedures, few inpatient hospital admissions are expected.

INCLUDED IN THIS GUIDE:

Under each section in this guide are CPT codes and Medicare National Average Payments for physicians, Ambulatory Surgery Centers, and Hospital Outpatient.

- 1. Radio Frequency Ablation Facet Joint Relmbursement 2025
- 2. Radio Frequency Ablation Knee Joint Relmbursement 2025
- 3. Radio Frequency Ablation Sacroiliac Joint Relmbursement 2025
- 4. Facet Intervention Procedures Medicare Prior Authorization Requirements

Coding and Payment Guide for Medicare Reimbursement: The following are the 2025 Medicare coding and national payment rates for Radio Frequency Ablation (Facet Joint) procedures performed in an ambulatory surgical center, physician office, or outpatient hospital.

THERAPEUTIC PROCEDURES

PROCEDURES AMBULATORY
SURGERY CENTER

OUTPATIENT HOSPITAL

CPT/HCPCS CODES ¹	DESCRIPTION	STATUS INDICATOR ³	ASC NATIONAL AVERAGE PAYMENT ²	STAT	ΓUS CATOR⁴	APC CODE⁵	OPPS NATIONAL AVERAGE PAYMENT ²
*64633	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, single facet joint	G2	\$925		J1	5431	\$1,953
(+)64634	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, each additional facet joint (List separately in addition to code for primary procedure)	N1	N/A Packaged		N	N/A Packaged	
64635	Destruction by neurolytic agent,paravertebralfacet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, single facetjoint	G2	\$925		J1	5431	\$1,953
(+)64636	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, each additional facet joint. (List separately in addition to code for primary procedure.)	N1 N/A Packaged			N	N/A Packaged	
64999	Unlisted procedure, nervous system. [Use when the provider performs facet joint nerve destruction without fluoroscopy or CT imaging guidance]	N/A Packaged			Т	5441	\$295

PHYSICIAN⁹

CPT/HCPCS CODES ¹	NATIONAL AVERAGE PAYMENT ² (NON- FACILITY)	NATIONAL AVERAGE PAYMENT ² (FACILITY)	GLOBAL PERIOD	WORK RVU ⁹	RVU ⁹
*64633	\$417	\$187	10	3.32	12.89
(+)64634	\$241	\$65	ZZZ ⁶	1.32	7.46
64635	\$421	\$187	10	3.32	13.00
(+)64636	\$226	\$57	ZZZ ⁶	1.16	7.00
64999	Carrier Price		YYY¹	0	0

DIAGNOSTIC PROCEDURES

Diagnostic Procedures below are often required prior to coverage for the therapeutic procedures above. The provider is responsible for verifying payer policy as to the appropriate code used for each procedure.

CPT°,1	DESCRIPTION
64490	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic: single level.
(+)64491	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic: second level. (List separately in addition to code for primary procedure.)
(+)64492	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic: third and any additional level(s). (List separately in addition to code for primary procedure.)
64493	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; single level.
(+)64494	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; second level. (List separately in addition to code for primary procedure.)
(+)64495	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; third and any additional level(s). (List separately in addition to code for primary procedure.)

MEDICARE LOCAL COVERAGE DETERMINATIONS⁸

Please check with your local contractor. In the absence of an LCD, Medicare contractors will follow the NCD.

Palmetto GBA (AL, GA, TN, SC, VA, WV, NC)	LCD# L38765 LCA #A58350
Novitas JL (CO, NM, OK, TX, AR, LA, MS, DE, DC, MD, NJ, PA)	LCD #L34892 LCA# A56670
Noridian JE (CA, NV, HI)	LCD# L38801 LCA# A58403
Noridian JF (AK, AZ, ID, MT, WY, ND, OR, SD, UT, and WA)	LCD# L38803 LCA# A58405
NGS (IL, MN, WI, CT, NY, ME, MA, NH, RI, VT)	LCD# L35936 LCA# A57826
WPS (MI, IN, IA, KS, NE, MO, MN)	LCD# L38841 LCA #A57553
CGS (KY, OH)	LCD# L38773 LCA# A58364
First Coast (FL, Puerto Rico, Virgin Islands)	LCD# L33930 LCA# A57787

To locate the LCDs listed above: Go to: http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx ENTER LCD # in Document ID (+) Add on code. Only reimbursed in combination with the appropriate primary code



Coding and Payment Guide for Medicare Reimbursement: The following are the 2025 Medicare coding and national payment rates for Radio Frequency Ablation (Knee Joint) procedures performed in an ambulatory surgical center, physician office, or outpatient hospital.

DIAGNOSTIC PROCEDURES

PROCEDURES AMBULATORY
SURGERY CENTER

EK	C	JUTPAI	IENI	HOS	PH	٩L

CPT®1	DESCRIPTION	STATUS INDICATOR ³	ASC NATIONAL AVERAGE PAYMENT ²	STATUS INDICATOR ⁴	APC CODE ⁵	OPPS NATIONAL AVERAGE PAYMENT ²
64454	Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed	G2	\$372	Т	5442	\$693

PHYSICIAN

CPT®¹	NATIONAL AVERAGE PAYMENT ² (NON- FACILITY)	NATIONAL AVERAGE PAYMENT ² (FACILITY)	GLOBAL PERIOD	WORK RVU ⁹	RVU ⁹
64454	\$212	\$80	000	1.52	6.54

THERAPEUTIC PROCEDURES

64624	Destruction by neurolytic agent, genicular nerve branches including guidance, when performed	G2	\$925	J1	5431	\$1,953
-------	--	----	-------	----	------	---------

PHYSICIAN

CPT ^{®1}	NATIONAL AVERAGE PAYMENT ² (NON- FACILITY)	NATIONAL AVERAGE PAYMENT ² (FACILITY)	GLOBAL PERIOD	WORK RVU ⁹	RVU ⁹
64624	\$371	\$143	10	1.52	6.54

MEDICARE LOCAL COVERAGE DETERMINATIONS⁸

In the absence of an LCD, Medicare determines medical necessity on a case-by-case basis.

First Coast Service Options (FL)	LCD #L33933 LCA #A57788
NGS (IL, MN, WI, CT, NY, ME, MA, NH, RI, VT)	LCD #L36850 LCA #A57452

 $To locate the LCDs \ listed above: Go \ to: http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx \ ENTER \ LCD \ \# \ in \ Document \ ID \ (+) \ Add \ on \ code. Only \ reimbursed \ in \ combination \ with \ the \ appropriate \ primary \ code.$



RADIO FREQUENCY ABLATION SACROILIAC JOINT REIMBURSEMENT 2025

Coding and Payment Guide for Medicare Reimbursement: The following are the 2025 Medicare coding and national payment rates for Radio Frequency Ablation (Sacroiliac Joint) procedures performed in an ambulatory surgical center, physician office, or outpatient hospital.

DIAGNOSTIC PROCEDURES

	AIVIBULATURY
PROCEDURES	SURGERY CENTER

CPT®1	DESCRIPTION	STATUS INDICATOR³	ASC NATIONAL AVERAGE PAYMENT ²	STATUS INDICATOR ⁴	APC CODE⁵	OPPS NATIONAL AVERAGE PAYMENT ²
64451	Injection(s), anesthetic agent(s) and/or steroid; nerves innervating the sacroiliac joint, with imaging guidance (ie, fluoroscopy or computed tomography)	G2	\$372	Т	5442	\$693

OUTPATIENT HOSPITAL

PHYSICIAN

CPT ^{®1}	NATIONAL AVERAGE PAYMENT ² (NON- FACILITY)	NATIONAL AVERAGE PAYMENT ² (FACILITY)	GLOBAL PERIOD	WORK RVU ⁹	RVU ⁹
64451	\$217	\$80	000	1.52	6.72

THERAPEUTIC PROCEDURES

64625	Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance (ie, fluoroscopy or computed tomography)	G2	\$925	J1	5431	\$1,953
-------	--	----	-------	----	------	---------

PHYSICIAN

CPT ^{®1}	NATIONAL AVERAGE PAYMENT ² (NON- FACILITY)	NATIONAL AVERAGE PAYMENT ² (FACILITY)	GLOBAL PERIOD	WORK RVU ⁹	RVU ⁹
64625	\$452	\$191	10	3.39	13.96



HOSPITAL OUTPATIENT MEDICARE PRIOR AUTHORIZATION REQUIREMENTS FOR FACET INTERVENTION PROCEDURES

Traditional Medicare, CMS will require a prior authorization/affirmation for facet joint interventions starting July 1,2023. Impacted procedures — Hospital based Joint Facet Injections and Radio Frequency Facet Ablations procedures requiring prior authorization.

Please refer to your Medicare Administrative Contractor (MAC) for up-to-date prior authorization information.

Effective date of CMS Affirmation / prior authorization requirement: 07/01/2023 Date Medicare MACs will begin to receive authorization requests: 06/18/2023

Hospital accounts Identify accounts that perform Paravertebral Facet Joint Injections and/Ablations

- Ensure awareness of the CMS requirement- July 1, 2023 RFA claims must include Authorization / Affirmation #
- At the Hospital Identify the individual responsible for obtaining the prior authorizations
- Share the contact information of the doctor's office scheduling patient procedures
- Share the approved BSC Medicare RFA prior authorization education document(s) with LCD and LCA links
- Ask Hospital contact if they will complete the required authorization or delegate to the physician's office
- Share the webinar trainings scheduled from their MAC. (If applicable)

Physician accounts identify providers scheduling Injections or Radio Frequency Ablations at Hospitals after 7-1-2023

- Educate Doctors performing Facet Interventions in Hospitals on the new CMS requirement starting July 1st
- Identify the office staff responsible for scheduling and obtaining the prior authorizations
- Share the contact information of the hospital scheduling the procedure
- Share the approved BSC Medicare RFA prior authorization education document(s) with LCD and LCA links
- Share the webinar trainings scheduled from their MAC (if applicable)

7/1/2023: Confirm authorization number has been received for procedures at Hospitals prior to procedure

Things to remember:

- Involve your Regional Reimbursement Manager (RRM) to educate Offices and Hospitals.
- CMS expects a 10-14 day turn around for case review for approvals
- The affirmation # must be placed on the hospital claim or it will be denied
- Retro Authorizations (after the fact) will not be allowed by CMS
- Facet Injections or Ablations performed in ASC, Physician office or Critical Access Hospital- NO authorization required

See important notes on the uses and limitations of this information on the next page.

THERAPEUTIC CPT CODES (RFA)

- 64633 Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance; cervical or thoracic single facet joint.
- (+)64634 Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance; cervical or thoracic each additional facet joint.
- 64635 Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance; lumbar or sacral single facet joint.
- (+)64636 Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance; lumbar or sacral each additional facet joint.

DIAGNOSTIC CPT CODES (INJECTION)

- 64490 Injections(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoscopy or CT), cervical or thoracic; single level.
- (+) 64491 Injections(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoscopy or CT), cervical or thoracic; second level. (List separately)
- 64492 Injections(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoscopy or CT), cervical or thoracic; third and any additional)
- (+)64493 Injections(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoscopy or CT), lumbar or sacral; single level.
- (+)64494 Injections(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoscopy or CT), lumbar or sacral; second level.
- (+)64495 Injections(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoscopy or CT), lumbar or sacral; third and any additional levels.

- *Payer coverage limitations exist for facet joint denervation/destruction in the thoracic spine. Check with payer prior to performing procedure.
- 1. CPT Copyright 2024 American Medical Association (AMA). All rights reserved. CPT® is a registered trademark of the American Medical Association. Applicable FARS/DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dissense medicial services. The AMA assumes no liability for data contained nor not contained therein.
- 2 "National Average Payment" is the amount Medicare determines to be the maximum allowance for any Medicare covered procedure. Actual payment will vary based on the maximum allowance less any applicable deductibles, coinsurance etc.
- 3. ASC Status indicators: NI: Packaged service/term, no separate payment made. C2: Non-office-based surgical procedure added in CY 2008 or later; payment based on OPPS relative payment weight. P3: Office-based surgical procedure added to
- 4. Outpatient Status Indicators: N: Items and Services Packaged into APC Rates. Payment is packaged into payment for other services. Therefore, there is no separate APC payment. T: Procedure or Service, Multiple Procedure Reduction applies J1: Hospital Part B services paid through a comprehensive APC.
- 5. APC Codes: 5431 Level 1 Nerve Procedures, 5441 Level 1 Nerve Injections, 5442: Level 2 nerve Injections
- 6. "ZZZ" are surgical codes, they are add-on codes that you must bill with another service. There is no post-operative work included in the MPFS payment
- 7. "YYY" are contractor-priced codes, for whichcontractors determine the global period. The global period for these codes will be 0, 10, or 90days.
- 8 List of local Medicare carriers is not an exhaustive list. Please go to the appropriate Medicarecontractor specific website to findthe most updated state coverage jurisdiction.
- Department of Health and Human Services. Centers for Medicare and Medicaid Services. The 2025 National Average Medicare physician payment rates have been calculated using a conversion factor of 32.3465 which reflects changes effective as of calendar year 2025

Indications for Use: The Boston Scientific Radiofrequency Generators, associated Radiofrequency Lesion Probes and RF Cannula are indicated for use in procedures to create radiofrequency lesions for the treatment of pain or for lesioning only peripheral nerve tissue for functional neurosurgical procedures. The Boston Scientific RF Injection Electrodes are used for percutaneous nerve blocks with local anesthetic solution or for radiofrequency lesioning of peripheral nerve tissue only. The Boston Scientific LCED and Stereotactic TCD Electrodes are indicated for use in radiofrequency (RF) heat legioning of penylutics the Cartal Nanous Extension of the Proposition Scientific LCED and Stereotactic TCD Electrodes are indicated for use in radiofrequency (RF) heat legioning of penylutics the Cartal Nanous Extension of the Proposition Scientific LCED and Stereotactic TCD Electrodes are indicated for use in radiofrequency (RF) heat legioning of penylutics the Cartal Nanous Extension of the Proposition Scientific LCED and Stereotactic TCD Electrodes are indicated for use in radiofrequency (RF) heat legioning of penylutics the Cartal Nanous Extension Scientific LCED and Stereotactic TCD Electrodes are indicated for use in radiofrequency (RF) heat legioning of penylutics the Cartal Nanous Extension Scientific LCED and Stereotactic TCD Electrodes are indicated for use in radiofrequency (RF) heat legioning of penylutics are indicated for use in radiofrequency (RF) heat legioning of penylutics are indicated for use in radiofrequency (RF) heat legioning of penylutics are indicated for use in radiofrequency (RF) heat legioning of penylutics are indicated for use in radiofrequency (RF) heat legioning of penylutics are indicated for use in radiofrequency (RF) heat legioning of penylutics are indicated for use in radiofrequency (RF) heat legioning of penylutics are indicated for use in radiofrequency (RF) heat legioning of penylutics are indicated for use in radiofrequency (RF) heat legioning of penylutics are indicated for use in r

Warnings: The Boston Scientific RF devices may cause interference with active devices such as neurostimulators, cardiac pacemakers, and defibrillators. Interference may affect the action of these active devices or may damage them. For appropriate guidance, consult the instructions for use for these active devices. Refer to the Instructions for Use provided with Boston Scientific generators, electrodes and cannulas for potential adverse effects, warnings and precautions prior to using these products. Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

Disclaimer: Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules, and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Boston Scientific encourages providers to submit accurate and appropriate claims for services. It is always the provider's responsibility to determine medical necessity, the proper site for delivery of any services, and to submit appropriate codes, charges, and modifiers for services rendered. It is also always the provider's responsibility to understand and comply with Medicare national coverage determinations (NCD), Medicare local coverage determinations (LCD), and any other coverage requirements established by relevant payers which can be updated frequently. Boston Scientific recommends that you consult with your payers, reimbursement specialists, and/or legal counsel regarding coding, coverage, and reimbursement matters. Boston Scientific does not promote the use of its products outside their FDA-approved label. Payer policies will vary and should be verified prior to treatment for limitations on diagnosis, coding, or site of service requirements. All trademarks are the property of their respective owners. The coding options listed within this guide are commonly used codes and are not intended to be an all-inclusive list. We recommend consulting your relevant manuals for appropriate coding options. This coding information may include codes for procedures for which Boston Scientific currently offers no cleared or approved products. In those instances, such codes have been included solely in the interest of providing users with comprehensive coding information and are not intended to promote the use of any Boston Scientific products for which they are not cleared or approved. The Health Care Provider (HCP) is solely responsible for sele

Sequestration Disclaimer: Rates referenced in these guides do not reflect Sequestration; automatic reductions in federal spending that will result in a 2% across-the-board reduction to ALL Medicare rates as of January 1, 2022. (Budget Control Act of 2011).



Advancing science for life™

25155 Rye Canyon Loop Valencia, CA 91355 USA

Copyright © 2025 by Boston Scientific Corporation or its affiliates. All rights reserved.

NM-1878106-AC